United States: Trends In REIT M&A (2022-2023) - Goodwin Procter LLP

Mondaq

12 Oct 2023 0 shares 1 views

United States: Trends In REIT M&A (2022-2023) - Goodwin Procter LLP

Mondaq

Published 12 Oct 2023

In our 2022 alert "REIT M&A Trends Through the Pandemic," we cataloged a total of 42 new REIT transactions announced between August 2020 and May 2022...

Full Article

United States: Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb) - Goodwin Procter LLP

Mondaq 31 Oct 2023

On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA, a subcutaneous formulation for maintenance therapy for..

More coverage

United States: Genentech And Biogen File Joint Stipulation Of Dismissal In BPCIA Litigation Regarding Tocilizumab - Goodwin Procter LLP

Mondaq 27 Oct 2023

As we previously reported, in July 2023 Genentech, Inc., Hoffmann-LaRoche, Inc., and Chugai Pharmaceutical Co., Ltd. (collectively,..

United States: SEC EXAMS Division Announces 2024 Priorities Ahead Of Schedule - Goodwin Procter LLP
Mondaq 27 Oct 2023
United States: New California Law To Require Venture Capital Firms To Disclose Founder Diversity Information - Goodwin Procter LLP
Mondaq 25 Oct 2023
United States: Antitrust & Competition Life Sciences Quarterly Update Q3 2023 - Goodwin Procter LLP
Mondaq 25 Oct 2023
United States: Debt Download Newsletters October 23, 2023 - Goodwin Procter LLP
Mondaq 25 Oct 2023

United States: Trends In REIT M&A (2022-2023) - Goodwin Procter LLP

United States: Trends In REIT M&A (2022-2023) - Goodwin Procter LLP

You might like

Related news coverage

United States: Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb) - Goodwin Procter LLP

Advertisement

More coverage

United States: Genentech And Biogen File Joint Stipulation Of Dismissal In BPCIA Litigation Regarding Tocilizumab - Goodwin Procter LLP